20.12.2024 14:26:26 CET | Thor Medical ASA | Major shareholding notifications
Oslo, Norway, 20 December 2024: Reference is made to the stock exchange
announcements by Thor Medical ASA (the "Company") on 20 December 2024 regarding
the registration of share capital increase following the private placement of
new shares by the Company (the "Private Placement") and the retail offering of
new shares (the "PrimaryBid Offering").
Roth Invest AS holds 11,794,640 shares in the Company, representing approx. 5.02
% of the issued share capital and votes prior to the Private Placement and the
PrimaryBid Offering.
Following the registration of share capital increase resulting from shares
issued in tranche 1 of the Private Placement and the shares issued in the
PrimaryBid Offering, Roth Invest AS shareholding in the Company represents
approx. 4.2% of the 280,492,395 issued shares and votes in the Company and has
fallen below the 5%.
Contacts
Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440,
brede.ellingseter@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.
To learn more, visit www.thormedical.no - http://www.thormedical.no -
https://www.thormedical.no.
ATTACHMENTS
Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18370169/5451/Download%20announce
ment%20as%20PDF.pdf